Open economic security in the area of critical medicines: Towards a balanced approach
30 April 2025
Policy Dialogue
Speakers: Lorena Boix Alonso, Deputy Director-General, DG SANTE, European Commission; Natasha Azzopardi-Muscat, Director of the Division of Country Health Policies and Systems, WHO Europe; Francesca Colombo, Head of Health Division, OECD; Gloria Ghéquière, Deputy Head of Cabinet, Federal Minister of Health, Belgium; Elena Kamilarova-Alomar, Policy Officer for Technology and Security, DG TRADE, European Commission; Enrico Baraldi, Chair of Marketing, University of Uppsala; Bruno Gautrais, Head of Unit for Medical Products, DG SANTE, European Commission; Thibaut L’Ortye, Senior Director of Public Affairs, AmCham EU; Elizabeth Kuiper, Associate Director & Head of the Social Europe and Well-being Programme, European Policy Centre
Moderator: Paweł Świeboda, Senior Fellow & Co-Director of the Brussels Economic Security Forum, European Policy Centre
On 11 March, the European Commission presented the Critical Medicines Act, aiming to enhance the resilience and security of the European Union’s pharmaceutical supply chain.
This Policy Dialogue took stock of the immediate reactions to the Critical Medicines Act contribute to shaping its early development. The event was built around the three Ps of the European Economic Security Strategy (Promote, Protect and Partner), coupled with a fourth one (Prepare). It explored the prospects for building supply security by diversifying supply chains, expanding international trade cooperation and promote policies that enable diversified raw material and finished product sourcing.
Keynote speakers and panelists explored approaches to maintain the benefits of interconnected global supply chains and ways of achieving economic security through fostering innovation, investment, and collaboration across borders. They also examined a balance between continued international openness and improved prospects of the European industry. Further, the discussion addressed the nature of procurement and pricing mechanisms, regulatory and investment barriers as well as workforce shortages, and environmental regulations.
#criticalmedicines #economicsecurity #EUhealth
Policy Dialogue
Speakers: Lorena Boix Alonso, Deputy Director-General, DG SANTE, European Commission; Natasha Azzopardi-Muscat, Director of the Division of Country Health Policies and Systems, WHO Europe; Francesca Colombo, Head of Health Division, OECD; Gloria Ghéquière, Deputy Head of Cabinet, Federal Minister of Health, Belgium; Elena Kamilarova-Alomar, Policy Officer for Technology and Security, DG TRADE, European Commission; Enrico Baraldi, Chair of Marketing, University of Uppsala; Bruno Gautrais, Head of Unit for Medical Products, DG SANTE, European Commission; Thibaut L’Ortye, Senior Director of Public Affairs, AmCham EU; Elizabeth Kuiper, Associate Director & Head of the Social Europe and Well-being Programme, European Policy Centre
Moderator: Paweł Świeboda, Senior Fellow & Co-Director of the Brussels Economic Security Forum, European Policy Centre
On 11 March, the European Commission presented the Critical Medicines Act, aiming to enhance the resilience and security of the European Union’s pharmaceutical supply chain.
This Policy Dialogue took stock of the immediate reactions to the Critical Medicines Act contribute to shaping its early development. The event was built around the three Ps of the European Economic Security Strategy (Promote, Protect and Partner), coupled with a fourth one (Prepare). It explored the prospects for building supply security by diversifying supply chains, expanding international trade cooperation and promote policies that enable diversified raw material and finished product sourcing.
Keynote speakers and panelists explored approaches to maintain the benefits of interconnected global supply chains and ways of achieving economic security through fostering innovation, investment, and collaboration across borders. They also examined a balance between continued international openness and improved prospects of the European industry. Further, the discussion addressed the nature of procurement and pricing mechanisms, regulatory and investment barriers as well as workforce shortages, and environmental regulations.
#criticalmedicines #economicsecurity #EUhealth
